Gå direkt till innehåll

Kategorier: nils carlin

  • Scandinavian Biopharma through its subsidiary ETVAX continues clinical development

    A clinical phase-I, randomized, placebo controlled, double-blinded study of the final composition vaccine, comprising 120 healthy volunteers is presently ongoing. All volunteers have been fully immunized and immunological analyses are ongoing. The study is designed to measure safety and immunogenicity of the vaccine when given either alone or in combination with the immune-enhancing adjuvant dmLT.